Trials / Completed
CompletedNCT00501566
Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites
SR121463B in Cirrhotic Ascites Treatment With Normonatraemia: A Placebo-Controlled, Dose-Comparison Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide. The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | satavaptan (SR121463B) |
Timeline
- Start date
- 2004-04-01
- Completion
- 2005-01-01
- First posted
- 2007-07-16
- Last updated
- 2007-07-16
Locations
12 sites across 12 countries: Argentina, Australia, Belgium, Canada, Croatia, Czechia, France, Germany, Hungary, Italy, Romania, Spain
Source: ClinicalTrials.gov record NCT00501566. Inclusion in this directory is not an endorsement.